SGLT-2 inhibitors and GLP-1 receptor agonists for Type 2 diabetes

被引：0
|
作者：
Davila, Esteban [1 ]
Mccormack, James [2 ]
机构：
[1] New York City Hlth Hosp Kings Cty, Dept Emergency Med, 451 Clarkson Ave, Brooklyn, NY 11203 USA
[2] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada
来源：
ACADEMIC EMERGENCY MEDICINE | 2024年 / 31卷 / 04期
关键词：
diabetes; GLP-1 receptor agonist; metformin; SGLT-2; inhibitor;
D O I：
10.1111/acem.14895
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
[No abstract available]
引用
收藏
页码：408 / 411
页数：4
相关论文
共 50 条
  • [31] Mortality Differences SGLT-2, DPP-4 Inhibitors and GLP-1 Receptor Agonists
    不详
    DIABETES STOFFWECHSEL UND HERZ, 2018, 27 (03): : 173 - 173
  • [32] Expected Health Benefits of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Older Adults
    Dadwani, Rahul S.
    Wan, Wen
    Skandari, M. Reza
    Huang, Elbert S.
    MDM POLICY & PRACTICE, 2023, 8 (02)
  • [33] Socioeconomic position and initiation of SGLT-2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes - a Danish nationwide observational study
    Falkentoft, A. C.
    Andersen, J.
    Malik, M. E.
    Selmer, C.
    Gaede, P. H.
    Staehr, P. B.
    Hlatky, M. A.
    Fosboel, E.
    Koeber, L.
    Torp-Pedersen, C.
    Gislason, G. H.
    Gerds, T. A.
    Shou, M.
    Bruun, N. E.
    Ruwald, A. C.
    EUROPEAN HEART JOURNAL, 2021, 42 : 2622 - 2622
  • [34] Efficacy and safety of GLP-1 receptor agonists combined with SGLT-2 inhibitors in elderly patients with type 2 diabetes: a meta-analysis
    Wu, Yaping
    Yang, Zhenxing
    Cao, Qingqing
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2024, 16 (11): : 6852 - 6866
  • [35] The protective effects of SGLT-2 inhibitors, GLP-1 receptor agonists, and RAAS blockers against renal injury in patients with type 2 diabetes
    Kuang, Zengguang
    Hou, Ningning
    Kan, Chengxia
    Han, Fang
    Qiu, Hongyan
    Sun, Xiaodong
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2023, 55 (03) : 617 - 629
  • [36] Kidney and Cardiovascular Outcomes With SGLT2 Inhibitors and/or GLP-1 Receptor Agonists in Type 2 Diabetes
    Neuen, Brendon L.
    Solomon, Scott D.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 84 (08) : 709 - 711
  • [37] GLP-1 agonists and SGLT-2 inhibitors in adults with sickle cell disease
    Sun, Ryan
    Srivastava, Anand
    Derebail, Vimal K.
    Han, Jin
    Molokie, Robert E.
    Gordeuk, Victor
    Saraf, Santosh L.
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (08) : 1610 - 1612
  • [38] Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes
    Kutz, Alexander
    Kim, Dae Hyun
    Wexler, Deborah J.
    Liu, Jun
    Schneeweiss, Sebastian
    Glynn, Robert J.
    Patorno, Elisabetta
    DIABETES CARE, 2023, 46 (11) : 2004 - 2014
  • [39] Socioeconomic dispartities in the use of SGLT-2 inhibitors and GLP-1 receptor antagonists in adults with type 2 diabetes in Germany
    Auzanneau, M.
    Seufert, J.
    Zimny, S.
    Haak, T.
    Zeyfang, A.
    Hugenberg, I.
    Pavel, M.
    Rosenbauer, J.
    Holl, R. W.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S74 - S74
  • [40] Impact of socioeconomic position on initiation of SGLT-2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes - a Danish nationwide observational study
    Falkentoft, Alexander C.
    Andersen, Julie
    Malik, Mariam Elmegaard
    Selmer, Christian
    Gaede, Peter Haulund
    Staehr, Peter Bisgaard
    Hlatky, Mark A.
    Fosbol, Emil
    Kober, Lars
    Torp-Pedersen, Christian
    Gislason, Gunnar H.
    Gerds, Thomas Alexander
    Schou, Morten
    Bruun, Niels E.
    Ruwald, Anne-Christine
    LANCET REGIONAL HEALTH-EUROPE, 2022, 14
12345